hydroxysteroid 17-beta dehydrogenase 12Genealiases: KAR · SDR12C1
Q-omics provides the consensus-scored HSD17B12 profile across patient tissues and cancer cell-line models. HSD17B12 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HSD17B12 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, HSD17B12 RNA expression shows 19,355 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KIRC, and UVM as cancer lineages where HSD17B12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSD17B12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSD17B12 survival associations across molecular data types. HSD17B12 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSD17B12 RNA expression–survival associations across cancer types. High HSD17B12 expression shows unfavorable associations in ACC, LIHC, HNSC, CESC and UVM, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for HSD17B12 RNA expression.
This table summarizes HSD17B12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HSD17B12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSD17B12 shows lower tumor expression in KIRC, THCA, LUSC and KICH and higher tumor expression in COAD and STAD. The KIRC box plot shows higher HSD17B12 RNA expression in normal versus tumor tissue (log2 FC = −0.870, t-test p < 0.001).
This table shows molecular features associated with HSD17B12 in patient tissues and cancer cell lines. In patient samples, HSD17B12 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, HSD17B12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LUNG_NSCLC_LUAD.
